Actively Recruiting
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
Led by Affiliated Hospital to Academy of Military Medical Sciences · Updated on 2022-09-22
36
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective single arm,multi-center,phase 2 study,and this study is to evaluate the efficacy and safety of Orelabrutinib,Rituximab combined with high-dose Methotrexate(RMO) as first line regimens in the treatments of newly diagnosed primary central nervous system lymphoma(PCNSL).Objective response and complete response are the primary endpoint.
CONDITIONS
Official Title
Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary central nervous system diffuse large B-cell lymphoma confirmed by brain biopsy
- Age between 18 and 70 years
- Signed informed consent
- At least one measurable lesion
- Neutrophil count ≥1.5 x 10^9/L, hemoglobin ≥80 g/L, platelets ≥75 x 10^9/L, bilirubin less than 2 times upper limit of normal, ALT less than 4 times upper limit of normal, AST less than 4 times upper limit of normal
- Expected survival time of at least 3 months
You will not qualify if you...
- Contraindications to any of the components in Orelabrutinib, Rituximab, or high-dose Methotrexate
- History of other cancers that might affect study compliance or result analysis
- Severe heart failure
- Previous antitumor treatments
- Positive for HIV antibody
- Pregnant or breastfeeding women
- Considered unsuitable for enrollment by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital 307
Beijing, Beijing Municipality, China, 100071
Actively Recruiting
Research Team
W
wenrong huang, Dr
CONTACT
S
shihua zhao, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here